The Vaccine Which was developed by the British Oxford Union / British AstraZeneca Limited protection against moderate forms of disease caused by the South African variant in young people, Recipient of a study from the University of the Witwatersrand in South Africa reported today.
On Friday, a spokesperson for AstraZeneca, citing the British Financial Times, indicated that a study of a sample of 2,000 people showed that the UK vaccine had Limited efficacy against mild forms of South African variant disease.
However, the same vaccine could be effective against severe forms of the disease, although there is not enough data on this study, which will be published tomorrow, to confirm it definitively.
Today, the South African Health Minister explained, “It is a temporary problem, we must suspend AstraZeneca vaccines until we solve those problems”, Zwaili MkhizeAt an online press conference, according to Agence France-Presse.
“These preliminary conclusions appear to confirm that the type of virus that appeared in South Africa could be transmitted between populations that have already been vaccinated.”The official added.
South Africa is the country most affected by the virus in Africa, with more than 1.5 million cases and more than 46,000 deaths.